2017
DOI: 10.1021/acs.jmedchem.6b01873
|View full text |Cite
|
Sign up to set email alerts
|

Topical Intestinal Aminoimidazole Agonists of G-Protein-Coupled Bile Acid Receptor 1 Promote Glucagon Like Peptide-1 Secretion and Improve Glucose Tolerance

Abstract: The role of the G-protein-coupled bile acid receptor TGR5 in various organs, tissues, and cell types, specifically in intestinal endocrine L-cells and brown adipose tissue, has made it a promising therapeutical target in several diseases, especially type-2 diabetes and metabolic syndrome. However, recent studies have shown deleterious on-target effects of systemic TGR5 agonists. To avoid these systemic effects while stimulating glucagon-like peptide-1 (GLP-1) secreting enteroendocrine L-cells, we have designed… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
37
0

Year Published

2018
2018
2021
2021

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 53 publications
(40 citation statements)
references
References 26 publications
0
37
0
Order By: Relevance
“…Thus, an ideal TGR5 agonist would be intestinal-specific agonist reaching L cells without affecting other systemic tissues. Indeed, Lasalle et al (2017) recently described a novel topical intestinal agonist of TGR5 that was given orally to obese and insulin-resistant mice, leading to prominent elevation in GLP-1 levels along with significant improvement in glucose tolerance. Intestinal TGR5 agonist did not cause a significant change in gallbladder size in lean mice.…”
Section: Ba Signaling and Regulation Of The Glycemic Responsementioning
confidence: 99%
“…Thus, an ideal TGR5 agonist would be intestinal-specific agonist reaching L cells without affecting other systemic tissues. Indeed, Lasalle et al (2017) recently described a novel topical intestinal agonist of TGR5 that was given orally to obese and insulin-resistant mice, leading to prominent elevation in GLP-1 levels along with significant improvement in glucose tolerance. Intestinal TGR5 agonist did not cause a significant change in gallbladder size in lean mice.…”
Section: Ba Signaling and Regulation Of The Glycemic Responsementioning
confidence: 99%
“…Despite this promising anti-diabetic activity of TGR5 mediate by GLP-1 ( 345 ), its pharmacological activation in diabetic patients has shown side effects at the level of gallbladder and heart, hampering its clinical use ( 346 ).…”
Section: Tgr5mentioning
confidence: 99%
“…Conformational changes resulting from methylation are well known in the chemistry community . In medicinal chemistry, the “magic” methyl concept has seen several successful examples ,,. Recently, methylation in late‐stage functionalization has been applied as a valuable tool in drug discovery .…”
Section: Introductionmentioning
confidence: 99%